Rational Molecular Editing: A New Paradigm in Drug Discovery

Chunhua Ma,Craig W. Lindsley,Junbiao Chang,Bin Yu

DOI: https://doi.org/10.1021/acs.jmedchem.4c01347

IF: 8.039

2024-06-22

Journal of Medicinal Chemistry

Abstract:J Med Chem . 2024 Jun 21. doi: 10.1021/acs.jmedchem.4c01347. Online ahead of print. NO

chemistry, medicinal

What problem does this paper attempt to address?

Quantitative Structure–activity Relationship: Promising Advances in Drug Discovery Platforms

Tao Wang,Mianbin Wu,Jianping Lin,Lirong Yang

DOI: https://doi.org/10.1517/17460441.2015.1083006

2015-01-01

Expert Opinion on Drug Discovery

Abstract:Quantitative structure-activity relationship (QSAR) modeling is one of the most popular computer-aided tools employed in medicinal chemistry for drug discovery and lead optimization. It is especially powerful in the absence of 3D structures of specific drug targets. QSAR methods have been shown to draw public attention since they were first introduced.In this review, the authors provide a brief discussion of the basic principles of QSAR, model development and model validation. They also highlight the current applications of QSAR in different fields, particularly in virtual screening, rational drug design and multi-target QSAR. Finally, in view of recent controversies, the authors detail the challenges faced by QSAR modeling and the relevant solutions. The aim of this review is to show how QSAR modeling can be applied in novel drug discovery, design and lead optimization.QSAR should intentionally be used as a powerful tool for fragment-based drug design platforms in the field of drug discovery and design. Although there have been an increasing number of experimentally determined protein structures in recent years, a great number of protein structures cannot be easily obtained (i.e., membrane transport proteins and G-protein coupled receptors). Fragment-based drug discovery, such as QSAR, could be applied further and have a significant role in dealing with these problems. Moreover, along with the development of computer software and hardware, it is believed that QSAR will be increasingly important.
Revolutionizing Playing with Skeleton Atoms: Molecular Editing Surgery in Medicinal Chemistry

Amgad M. Rabie

DOI: https://doi.org/10.2174/0113895575316229240611113946

2024-06-12

Mini-Reviews in Medicinal Chemistry

Abstract:Abstract: Finding the most perfect drug candidates in the fields of drug discovery and medicinal chemistry will remain the main interest of drug designers. This concern necessitates organic and medicinal chemists, in most examples, to precisely design and search for drug candidates that are very analogous to the present effective drugs for solving, mainly, their proven critical pharmacological and clinical issues through slightly changing one or two atoms of the principal functional skeletons of the molecules of present therapeutics by atom swapping, removal, and/or addition procedures in organic chemical synthesis. This accurate modern chemicosimilarity tactic in drug discovery surely saves time while keeping us very close, or sometimes highly superior, to the parent pharmacophoric bioactivity (i.e., keeping considerable analogy to the parent therapeutic molecule). From this perspective and logic, the science of skeletal editing of molecules (i.e., skeletal molecular editing) arose in the era of artificial intelligence (AI) and its dramatic predictions. As a pioneer in this modern branch in pharmaceutical and therapeutic organic chemistry, in this up-to-date minireview and perspective article, an attempt was made to introduce skeletal editing and its synthetic surgeries (over molecules) to the audience (including irrelevant readers) in a simpler and more attractive way as a novel chemical technology, highlighting the previous synthetic trials (in general), demonstrating the three main techniques, and, finally, discussing the future therapeutic needs and scenarios from a medicinal chemist's viewpoint.

chemistry, medicinal
Rethinking Medicinal Chemistry in the Cheminformatics Age

Tudor I. Oprea,David Weininger

DOI: https://doi.org/10.1021/acs.jmedchem.4c02179

IF: 8.039

2024-10-04

Journal of Medicinal Chemistry

Abstract:J Med Chem . 2024 Oct 2. doi: 10.1021/acs.jmedchem.4c02179. Online ahead of print. NO

chemistry, medicinal
Rational, computer-enabled peptide drug design: principles, methods, applications and future directions

David J Diller,Jon Swanson,Alexander S Bayden,Mark Jarosinski,Joseph Audie

DOI: https://doi.org/10.4155/fmc.15.142

2015-10-01

Future Medicinal Chemistry

Abstract:Peptides provide promising templates for developing drugs to occupy a middle space between small molecules and antibodies and for targeting ‘undruggable’ intracellular protein–protein interactions. Importantly, rational or in cerebro design, especially when coupled with validated in silico tools, can be used to efficiently explore chemical space and identify islands of ‘drug-like’ peptides to satisfy diverse drug discovery program objectives. Here, we consider the underlying principles of and recent advances in rational, computer-enabled peptide drug design. In particular, we consider the impact of basic physicochemical properties, potency and ADME/Tox opportunities and challenges, and recently developed computational tools for enabling rational peptide drug design. Key principles and practices are spotlighted by recent case studies. We close with a hypothetical future case study.

chemistry, medicinal
CRISPR-Cas13: Pioneering RNA Editing for Nucleic Acid Therapeutics

Guanglin Zhu,Xinzhi Zhou,Mingzhang Wen,Jianjun Qiao,Guo Li,Yuan Yao

DOI: https://doi.org/10.34133/bdr.0041

2024-09-03

Abstract:The CRISPR-Cas13 system has emerged as a revolutionary tool for RNA editing, offering new opportunities for the development of nucleic acid therapeutics. Unlike DNA-targeting CRISPR-Cas9, Cas13 targets and cleaves RNA, enabling gene silencing and preventing genomic instability. Its applications include suppressing disease-causing genes, correcting splicing errors, and modulating immune responses. Despite these advances, challenges persist, such as the need to refine specificity, mitigate off-target impacts, and ensure effective delivery. This review provides an overview of the CRISPR-Cas13 mechanism, elucidating its role in RNA-targeted therapies and its transformative potential for disease treatment. Furthermore, it addresses the ongoing challenges that the scientific community is striving to overcome.
Rational strategies for improving the efficiency of design and discovery of nanomedicines

Xiaoting Shan,Ying Cai,Binyu Zhu,Lingli Zhou,Xujie Sun,Xiaoxuan Xu,Qi Yin,Dangge Wang,Yaping Li

DOI: https://doi.org/10.1038/s41467-024-54265-3

2024-11-18

Abstract:The rise of rational strategies in nanomedicine development, such as high-throughput methods and computer-aided techniques, has led to a shift in the design and discovery patterns of nanomedicines from a trial-and-error mode to a rational mode. This transition facilitates the enhancement of efficiency in the preclinical discovery pipeline of nanomaterials, particularly in improving the hit rate of nanomaterials and the optimization efficiency of promising candidates. Herein, we describe a directed evolution mode of nanomedicines driven by data to accelerate the discovery of nanomaterials with high delivery efficiency. Computer-aided design strategies are introduced in detail as one of the cutting-edge directions for the development of nanomedicines. Ultimately, we look forward to expanding the tools for the rational design and discovery of nanomaterials using multidisciplinary approaches. Rational design strategies may potentially boost the delivery efficiency of next-generation nanomedicines.
A circularly permuted CasRx platform for efficient, site-specific RNA editing

Yuanming Wang,Kaiwen Ivy Liu,Mengying Mandy Liu,Kean Hean Ooi,Tram Anh Nguyen,Jiunn En Chee,Shun Xiang Danny Teo,Shan He,Jie Wen Douglas Tay,Seok Yee Teo,Kai Shin Liew,Xiao Yu Ge,Zhi Jian Ng,Hasmik Avagyan,Hao Liu,Zirong Yi,Keziah Chang,Eng Piew Louis Kok,Runjia Chen,Chun En Yau,Jun Wei Koh,Yue Wan,Meng How Tan

DOI: https://doi.org/10.1038/s41587-024-02430-w

IF: 46.9

2024-10-10

Nature Biotechnology

Abstract:Inactive Cas13 orthologs have been fused to a mutant human ADAR2 deaminase domain at the C terminus to enable programmable adenosine-to-inosine (A-to-I) RNA editing in selected transcripts. Although promising, existing RNA-editing tools generally suffer from a trade-off between efficacy and specificity, and off-target editing remains an unsolved problem. Here we describe the development of an optimized RNA-editing platform by rational protein engineering, CasRx-based Programmable Editing of RNA Technology (xPERT). We demonstrate that the topological rearrangement of a CasRx K940L mutant by circular permutation results in a robust scaffold for the tethering of a deaminase domain. We benchmark our tool against the REPAIR system and show that xPERT exhibits strong on-target activity like REPAIRv1 but low off-target editing like REPAIRv2. Our xPERT platform can be used to alter RNA sequence information without risking genome damage, effect temporary cellular changes and customize protein function.

biotechnology & applied microbiology
Recent Advances in the Rational Drug Design Based on Multi-target Ligands.

Ting Yang,Xin Sui,Bing Yu,Youqing Shen,Hailin Cong

DOI: https://doi.org/10.2174/0929867327666200102120652

IF: 4.74

2020-01-01

Current Medicinal Chemistry

Abstract:Multi-target drugs have gained considerable attention in the last decade owing to their advantages in the treatment of complex diseases and health conditions linked to drug resistance. Single-target drugs, although highly selective, may not necessarily have better efficacy or fewer side effects. Therefore, more attention is being paid to developing drugs that work on multiple targets at the same time, but developing such drugs is a huge challenge for medicinal chemists. Each target must have sufficient activity and have sufficiently characterized pharmacokinetic parameters. Multi-target drugs, which have long been known and effectively used in clinical practice, are briefly discussed in the present article. In addition, in this review, we will discuss the possible applications of multi-target ligands to guide the repositioning of prospective drugs.
Correction to "The New Frontier: Merging Molecular Glue Degrader and Antibody-Drug Conjugate Modalities To Overcome Strategic Challenges"

Yam B Poudel,Ruchita R Thakore,Eugene P Chekler

DOI: https://doi.org/10.1021/acs.jmedchem.4c02447

IF: 8.039

2024-10-19

Journal of Medicinal Chemistry

Abstract:J Med Chem . 2024 Oct 18. doi: 10.1021/acs.jmedchem.4c02447. Online ahead of print. NO

chemistry, medicinal
Retro Drug Design: From Target Properties to Molecular Structures

Yuhong Wang,Sam Michael,Ruili Huang,Jinghua Zhao,Katlin Recabo,Danielle Bougie,Qiang Shu,Paul Shinn,Hongmao Sun

DOI: https://doi.org/10.48550/arXiv.2105.05220

2021-05-12

Abstract:To generate drug molecules of desired properties with computational methods is the holy grail in pharmaceutical research. Here we describe an AI strategy, retro drug design, or RDD, to generate novel small molecule drugs from scratch to meet predefined requirements, including but not limited to biological activity against a drug target, and optimal range of physicochemical and ADMET properties. Traditional predictive models were first trained over experimental data for the target properties, using an atom typing based molecular descriptor system, ATP. Monte Carlo sampling algorithm was then utilized to find the solutions in the ATP space defined by the target properties, and the deep learning model of Seq2Seq was employed to decode molecular structures from the solutions. To test feasibility of the algorithm, we challenged RDD to generate novel drugs that can activate {\mu} opioid receptor (MOR) and penetrate blood brain barrier (BBB). Starting from vectors of random numbers, RDD generated 180,000 chemical structures, of which 78% were chemically valid. About 42,000 (31%) of the valid structures fell into the property space defined by MOR activity and BBB permeability. Out of the 42,000 structures, only 267 chemicals were commercially available, indicating a high extent of novelty of the AI-generated compounds. We purchased and assayed 96 compounds, and 25 of which were found to be MOR agonists. These compounds also have excellent BBB scores. The results presented in this paper illustrate that RDD has potential to revolutionize the current drug discovery process and create novel structures with multiple desired properties, including biological functions and ADMET properties. Availability of an AI-enabled fast track in drug discovery is essential to cope with emergent public health threat, such as pandemic of COVID-19.

Biomolecules
Recent Advances In The Rational Drug Design Based On Multi-Target Ligands

Ting Yang,Xin Sui,Bing Yu,Youqing Shen,Hailin Cong

DOI: https://doi.org/10.2174/0929867327666200102120652

IF: 4.74

2020-01-01

Current Medicinal Chemistry

Abstract:Multi-target drugs have gained considerable attention in the last decade owing to their advantages in the treatment of complex diseases and health conditions linked to drug resistance. Single-target drugs, although highly selective, may not necessarily have better efficacy or fewer side effects. Therefore, more attention is being paid to developing drugs that work on multiple targets at the same time, but developing such drugs is a huge challenge for medicinal chemists. Each target must have sufficient activity and have sufficiently characterized pharmacokinetic parameters. Multi-target drugs, which have long been known and effectively used in clinical practice, are briefly discussed in the present article. In addition, in this review, we will discuss the possible applications of multi-target ligands to guide the repositioning of prospective drugs.
A rational blueprint for the design of chemically-controlled protein switches

Sailan Shui,Pablo Gainza,Leo Scheller,Che Yang,Yoichi Kurumida,Stéphane Rosset,Sandrine Georgeon,Raphaël B. Di Roberto,Rocío Castellanos-Rueda,Sai T. Reddy,Bruno E. Correia

DOI: https://doi.org/10.1038/s41467-021-25735-9

IF: 16.6

2021-10-01

Nature Communications

Abstract:Abstract Small-molecule responsive protein switches are crucial components to control synthetic cellular activities. However, the repertoire of small-molecule protein switches is insufficient for many applications, including those in the translational spaces, where properties such as safety, immunogenicity, drug half-life, and drug side-effects are critical. Here, we present a computational protein design strategy to repurpose drug-inhibited protein-protein interactions as OFF- and ON-switches. The designed binders and drug-receptors form chemically-disruptable heterodimers (CDH) which dissociate in the presence of small molecules. To design ON-switches, we converted the CDHs into a multi-domain architecture which we refer to as activation by inhibitor release switches (AIR) that incorporate a rationally designed drug-insensitive receptor protein. CDHs and AIRs showed excellent performance as drug responsive switches to control combinations of synthetic circuits in mammalian cells. This approach effectively expands the chemical space and logic responses in living cells and provides a blueprint to develop new ON- and OFF-switches.

multidisciplinary sciences
"Rational Design and Synthesis of Bioactive Molecules"

Irena Kostova

DOI: https://doi.org/10.3390/ijms25189927

IF: 5.6

2024-09-15

International Journal of Molecular Sciences

Abstract:The rational design of novel bioactive molecules is a critical but challenging task in drug discovery [...]

biochemistry & molecular biology,chemistry, multidisciplinary
Precise RNA editing by recruiting endogenous ADARs with antisense oligonucleotides

Tobias Merkle,Sarah Merz,Philipp Reautschnig,Andreas Blaha,Qin Li,Paul Vogel,Jacqueline Wettengel,Jin Billy Li,Thorsten Stafforst

DOI: https://doi.org/10.1038/s41587-019-0013-6

IF: 46.9

2019-01-28

Nature Biotechnology

Abstract:Site-directed RNA editing might provide a safer or more effective alternative to genome editing in certain clinical scenarios. Until now, RNA editing has relied on overexpression of exogenous RNA editing enzymes or of endogenous human ADAR (adenosine deaminase acting on RNA) enzymes. Here we describe the engineering of chemically optimized antisense oligonucleotides that recruit endogenous human ADARs to edit endogenous transcripts in a simple and programmable way, an approach we call RESTORE (recruiting endogenous ADAR to specific transcripts for oligonucleotide-mediated RNA editing). We observed almost no off-target editing, and natural editing homeostasis was not perturbed. We successfully applied RESTORE to a panel of standard human cell lines and human primary cells and demonstrated repair of the clinically relevant PiZZ mutation, which causes α1-antitrypsin deficiency, and editing of phosphotyrosine 701 in STAT1, the activity switch of the signaling factor. RESTORE requires only the administration of an oligonucleotide, circumvents ectopic expression of proteins, and represents an attractive approach for drug development.

biotechnology & applied microbiology
Late-stage modification of bioactive compounds: Improving druggability through efficient molecular editing

Tongyu Huo,Xinyi Zhao,Zengrui Cheng,Jialiang Wei,Minghui Zhu,Xiaodong Dou,Ning Jiao

DOI: https://doi.org/10.1016/j.apsb.2023.11.021

IF: 14.903

2023-11-20

Acta Pharmaceutica Sinica B

Abstract:Synthetic chemistry plays an indispensable role in drug discovery, contributing to hit compounds identification, lead compounds optimization, candidate drugs preparation, and so on. As Nobel Prize laureate James Black emphasized, "the most fruitful basis for the discovery of a new drug is to start with an old drug" 1 . Late-stage modification or functionalization of drugs, natural products and bioactive compounds have garnered significant interest due to its ability to introduce diverse elements into bioactive compounds promptly. Such modifications alter the chemical space and physiochemical properties of these compounds, ultimately influencing their potency and druggability. To enrich a toolbox of chemical modification methods for drug discovery, this review focuses on the incorporation of halogen, oxygen, and nitrogen—the ubiquitous elements in pharmacophore components of the marketed drugs—through late-stage modification in recent two decades, and discusses the state and challenges faced in these fields. We also emphasize that increasing cooperation between chemists and pharmacists may be conducive to the rapid discovery of new activities of the functionalized molecules. Ultimately, we hope this review would serve as a valuable resource, facilitating the application of late-stage modification in the construction of novel molecules and inspiring innovative concepts for designing and building new drugs.

pharmacology & pharmacy
A Novel Engineered U7 Small Nuclear RNA Scaffold Greatly Increases and ADAR-Mediated Programmable RNA Base Editing

Susan M Byrne,Stephen M Burleigh,Robert Fragoza,Yue Jiang,Yiannis Savva,Ricky Pabon,Joseph Rainaldi,Andrew Portell,Prashant Mali,Adrian W Briggs

DOI: https://doi.org/10.1101/2024.09.29.615721

2024-10-01

Abstract:Custom RNA base editing using the endogenous human Adenosine Deaminase Acting on RNA (ADAR) enzyme presents a promising approach for precision therapeutics, alleviating concerns of permanent DNA damage or immunogenicity from foreign bacterial proteins such as CRISPR/Cas. ADAR can be directed to act on therapeutic RNA targets by antisense guide RNAs (gRNAs) that create a substrate for ADAR′s adenosine-to-inosine (effectively A-to-G) deamination activity. Delivery of gRNAs via a DNA expression construct provided by Adeno-Associated Virus (AAV) might allow life-long duration of the therapy. However, a major challenge for RNA editing using gene-encoded gRNAs and endogenous levels of ADAR is achieving sufficient gRNA activity inside cells, especially in therapeutic situations where AAV delivery may provide as low as one viral genome per cell. Here we show that embedding antisense gRNAs into a U7 small nuclear RNA (snRNA) framework and adding hnRNP A1 binding domains greatly increases the efficiency of custom RNA editing. This increased editing efficiency allows for detectable RNA editing from a single genomic insertion of gRNA construct per cell, which enabled a pooled library screen of 750+ gRNA variations to further improve the SmOPT U7 hairpin system. The screen revealed critical residues responsible for RNA editing and generated new SmOPT and U7 hairpin variants that further boosted RNA editing. The final design, combined with an improved synthetic U7 promoter, resulted in up to 76% targeted editing with a single integrated copy of construct per cell, representing a 10- to 100-fold increase over existing circular gRNA approaches. Using systemic AAV delivery, we achieved an unprecedented 75% RNA editing in the total brain of a mouse model of Hurler syndrome. Our novel SmOPT U7 system also improved published antisense oligos for DMD exon skipping, currently in clinical trials, by up to 25-fold in differentiated myoblasts, and therefore represents a universal scaffold for ADAR-based RNA editing as well as other antisense RNA therapies.

Bioengineering
Abstract Wrk2-04: Virtual screening of ultra-large chemical spaces for novel chemotype discovery

J. Irwin

DOI: https://doi.org/10.1158/1538-7445.sabcs23-wrk2-04

IF: 11.2

2024-05-03

Cancer Research

Abstract:Recently, 'tangible' virtual libraries have made billions of molecules readily available. Prioritizing these molecules for synthesis and testing demands computational approaches, such as docking. We will present recent results in which protein structure is interrogated using molecular docking, resulting in new high-affinity compounds that exhibit new biology in animal models. Singh I, Seth A, Billesbølle CB, Braz J, Rodriguiz RM, Roy K, Bekele B, Craik V, Huang XP, Boytsov D, Pogorelov VM, Lak P, O'Donnell H, Sandtner W, Irwin JJ, Roth BL, Basbaum AI, Wetsel WC, Manglik A, Shoichet BK, Rudnick G. Structure-based discovery of conformationally selective inhibitors of the serotonin transporter. Cell. 2023 May 11;186(10):2160-2175.e17. doi: 10.1016/j.cell.2023.04.010. Epub 2023 May 2. PMID: 37137306; PMCID: PMC10306110. Fink EA, Xu J, Hübner H, Braz JM, Seemann P, Avet C, Craik V, Weikert D, Schmidt MF, Webb CM, Tolmachova NA, Moroz YS, Huang XP, Kalyanaraman C, Gahbauer S, Chen G, Liu Z, Jacobson MP, Irwin JJ, Bouvier M, Du Y, Shoichet BK, Basbaum AI, Gmeiner P. Structure-based discovery of nonopioid analgesics acting through the α2A-adrenergic receptor. Science. 2022 Sep 30;377(6614):eabn7065. doi: 10.1126/science.abn7065. Epub 2022 Sep 30. PMID: 36173843; PMCID: PMC10360211. Kaplan AL, Confair DN, Kim K, Barros-Álvarez X, Rodriguiz RM, Yang Y, Kweon OS, Che T, McCorvy JD, Kamber DN, Phelan JP, Martins LC, Pogorelov VM, DiBerto JF, Slocum ST, Huang XP, Kumar JM, Robertson MJ, Panova O, Seven AB, Wetsel AQ, Wetsel WC, Irwin JJ, Skiniotis G, Shoichet BK, Roth BL, Ellman JA. Bespoke library docking for 5-HT2A receptor agonists with antidepressant activity. Nature. 2022 Oct;610(7932):582-591. doi: 10.1038/s41586-022-05258-z. Epub 2022 Sep 28. PMID: 36171289; PMCID: PMC9996387. Citation Format: J. Irwin. Virtual screening of ultra-large chemical spaces for novel chemotype discovery [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl) nr Wrk2-04.

oncology
Rational design of base, sugar and backbone modifications improves ADAR-mediated RNA editing

Genliang Lu,Chikdu Shivalila,Prashant Monian,Hui Yu,Ian Harding,Stearne Briem,Michael Byrne,Alyse Faraone,Stephen Friend,Olivia Huth,Naoki Iwamoto,Tomomi Kawamoto,Jayakanthan Kumarasamy,Anthony Lamattina,Kenneth Longo,Leah McCarthy,Andrew McGlynn,Allison Molski,Qianli Pan,Tom Pu,Erin Purcell-Estabrook,Jeff Rossi,Stephany Standley,Carina Thomas,Alexandra Walen,Hailin Yang,Pachamuthu Kandasamy,Chandra Vargeese

DOI: https://doi.org/10.1093/nar/gkae681

IF: 14.9

2024-08-31

Nucleic Acids Research

Abstract:AIMers are short, chemically modified oligonucleotides that induce A-to-I RNA editing through interaction with endogenous adenosine deaminases acting on RNA (ADAR) enzymes. Here, we describe the development of new AIMer designs with base, sugar and backbone modifications that improve RNA editing efficiency over our previous design. AIMers incorporating a novel pattern of backbone and 2′ sugar modifications support enhanced editing efficiency across multiple sequences. Further efficiency gains were achieved through incorporation of an N-3-uridine (N3U), in place of cytidine (C), in the 'orphan base' position opposite the edit site. Molecular modeling suggests that N3U might enhance ADAR catalytic activity by stabilizing the AIMer-ADAR interaction and potentially reducing the energy required to flip the target base into the active site. Supporting this hypothesis, AIMers containing N3U consistently enhanced RNA editing over those containing C across multiple target sequences and multiple nearest neighbor sequence combinations. AIMers combining N3U and the novel pattern of 2′ sugar chemistry and backbone modifications improved RNA editing both in vitro and in vivo . We provide detailed N3U synthesis methods and, for the first time, explore the impact of N3U and its analogs on ADAR-mediated RNA editing efficiency and targetable sequence space.

biochemistry & molecular biology
EditR: A novel base editing quantification software using Sanger sequencing

Mitchell G. Kluesner,Derek A. Nedveck,Walker S. Lahr,John R. Garbe,Juan E. Abrahante,Beau R. Webber,Branden S. Moriarity

DOI: https://doi.org/10.1101/213496

2017-11-05

Abstract:ABSTRACT CRISPR/Cas9-Cytidine deaminase fusion enzymes - termed Base Editors – allow targeted editing of genomic deoxcytidine to deoxthymidine (C→T) without the need for double stranded break induction. Base editors represent a paradigm-shift in gene editing technology, due to their unprecedented efficiency to mediate targeted, single-base conversion; however, current analysis of base editing outcomes rely on methods that are either imprecise or expensive and time consuming. To overcome these limitations, we developed a simple, cost effective, and accurate program to measure base editing efficiency from fluorescence-based Sanger sequencing, termed EditR. We provide EditR as a free online tool or downloadable desktop application requiring a single Sanger sequencing file and guide RNA sequence ( baseeditr.com ). EditR is more accurate than enzymatic assays, and provides added insight to the position, type and efficiency of base editing. Collectively, we demonstrate that EditR is a robust, inexpensive tool that will facilitate the broad application of base editing technology, thereby fostering further innovation in this burgeoning field.
A Novel Rational PROTACs Design and Validation via AI-Driven Drug Design Approach

Cheng-Li Chou,Chieh-Te Lin,Chien-Ting Kao,Chu-Chung Lin

DOI: https://doi.org/10.1021/acsomega.3c10183

IF: 4.1

2024-09-06

ACS Omega

Abstract:The rational design of novel drug candidates presents a formidable challenge in modern drug discovery. Proteolysis-targeting chimeras (PROTACs) drug design is particularly demanding due to their limited crystal structure availability and design of a viable small molecule to bridge the protein of interest (POI) and ubiquitin-protein ligase (E3). An integrated approach that combines superimposition techniques and deep neural networks is demonstrated in this study to leverage the power of deep learning and structural biology to generate structurally diverse molecules with enhanced binding affinities. The superimposition technique ensures the congruence of initial and new protein-ligand pairs, which are evaluated via subsequent comprehensive screening using the root-mean-square deviation (RMSD), binding free energy (BFE), and buried solvent-accessible surface area (SASA). The final candidates are subjected to the incorporation of molecular dynamics (MD) and free energy perturbation (FEP) simulations to provide a quantitative evaluation of relative binding energies, reinforcing the efficacy and reliability of the generated molecules. The outcomes of the generated novel PROTACs molecules exhibit comparable structural attributes while demonstrating superior binding affinities within the binding pockets when contrasted with those of the established cocrystal ternary complexes. To enhance the generalizability of the workflow, we chose the ternary structure of the cellular inhibitor of apoptosis protein 1 (cIAP1) and Bruton's Tyrosine Kinase (BTK) for validating the chemical properties generated from the processes. The new linker molecules additionally showed superior affinity from the simulations. In summary, this methodology serves as an effective workflow to align computational predictions with current limitations, thereby introducing a novel paradigm in AI-driven drug design.

Rational Molecular Editing: A New Paradigm in Drug Discovery

Quantitative Structure–activity Relationship: Promising Advances in Drug Discovery Platforms

Revolutionizing Playing with Skeleton Atoms: Molecular Editing Surgery in Medicinal Chemistry

Rethinking Medicinal Chemistry in the Cheminformatics Age

Rational, computer-enabled peptide drug design: principles, methods, applications and future directions

CRISPR-Cas13: Pioneering RNA Editing for Nucleic Acid Therapeutics

Rational strategies for improving the efficiency of design and discovery of nanomedicines

A circularly permuted CasRx platform for efficient, site-specific RNA editing

Recent Advances in the Rational Drug Design Based on Multi-target Ligands.

Correction to "The New Frontier: Merging Molecular Glue Degrader and Antibody-Drug Conjugate Modalities To Overcome Strategic Challenges"

Retro Drug Design: From Target Properties to Molecular Structures

Recent Advances In The Rational Drug Design Based On Multi-Target Ligands

A rational blueprint for the design of chemically-controlled protein switches

"Rational Design and Synthesis of Bioactive Molecules"

Precise RNA editing by recruiting endogenous ADARs with antisense oligonucleotides

Late-stage modification of bioactive compounds: Improving druggability through efficient molecular editing

A Novel Engineered U7 Small Nuclear RNA Scaffold Greatly Increases and ADAR-Mediated Programmable RNA Base Editing

Abstract Wrk2-04: Virtual screening of ultra-large chemical spaces for novel chemotype discovery

Rational design of base, sugar and backbone modifications improves ADAR-mediated RNA editing

EditR: A novel base editing quantification software using Sanger sequencing

A Novel Rational PROTACs Design and Validation via AI-Driven Drug Design Approach